Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.

NCT00594165 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00594165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00594165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
November 30, 2008
Enrollment
217 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage parkinson's disease